| pubmed-article:19167904 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19167904 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:19167904 | lifeskim:mentions | umls-concept:C0010453 | lld:lifeskim |
| pubmed-article:19167904 | lifeskim:mentions | umls-concept:C0036186 | lld:lifeskim |
| pubmed-article:19167904 | lifeskim:mentions | umls-concept:C0020507 | lld:lifeskim |
| pubmed-article:19167904 | lifeskim:mentions | umls-concept:C0541315 | lld:lifeskim |
| pubmed-article:19167904 | lifeskim:mentions | umls-concept:C0599946 | lld:lifeskim |
| pubmed-article:19167904 | lifeskim:mentions | umls-concept:C1527362 | lld:lifeskim |
| pubmed-article:19167904 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19167904 | pubmed:dateCreated | 2009-3-3 | lld:pubmed |
| pubmed-article:19167904 | pubmed:abstractText | Neointimal hyperplasia is the first step in a cascade leading to a reduced patency rate of saphenous vein grafts in comparison to arterial grafts in coronary artery bypass grafting. Using cultured human saphenous vein grafts as a model for coronary artery bypass grafting, we investigated if the mammalian target of rapamycin inhibitor everolimus attenuates neointimal hyperplasia. | lld:pubmed |
| pubmed-article:19167904 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19167904 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19167904 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19167904 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19167904 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19167904 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19167904 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19167904 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19167904 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19167904 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:19167904 | pubmed:issn | 1873-734X | lld:pubmed |
| pubmed-article:19167904 | pubmed:author | pubmed-author:TroppmairJako... | lld:pubmed |
| pubmed-article:19167904 | pubmed:author | pubmed-author:MacfeldaKarin... | lld:pubmed |
| pubmed-article:19167904 | pubmed:author | pubmed-author:LauferGuenthe... | lld:pubmed |
| pubmed-article:19167904 | pubmed:author | pubmed-author:BerneckerOliv... | lld:pubmed |
| pubmed-article:19167904 | pubmed:author | pubmed-author:SemsrothSever... | lld:pubmed |
| pubmed-article:19167904 | pubmed:author | pubmed-author:BonattiJohann... | lld:pubmed |
| pubmed-article:19167904 | pubmed:author | pubmed-author:StiglerRobert... | lld:pubmed |
| pubmed-article:19167904 | pubmed:author | pubmed-author:Ruttmann-Ulme... | lld:pubmed |
| pubmed-article:19167904 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19167904 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:19167904 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19167904 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19167904 | pubmed:pagination | 515-20 | lld:pubmed |
| pubmed-article:19167904 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:meshHeading | pubmed-meshheading:19167904... | lld:pubmed |
| pubmed-article:19167904 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19167904 | pubmed:articleTitle | Everolimus attenuates neointimal hyperplasia in cultured human saphenous vein grafts. | lld:pubmed |
| pubmed-article:19167904 | pubmed:affiliation | Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria. severin.semsroth@i-med.ac.at | lld:pubmed |
| pubmed-article:19167904 | pubmed:publicationType | Journal Article | lld:pubmed |
